Anti TNF therapy
NASS worked with NICE on the multiple technology appraisal for the new anti TNF drugs which reported in May 2008. This gave access to adalimumab (Humira) and etanercept (Enbrel). (NICE guidance for adalimumab, etanercept and infliximab).
NASS worked with NICE again in 2011 when another anti TNF golimumab (Simponi) , was approved for AS.
Clinical guidelines
NASS has also asked NICE to draw up clinical guidelines for AS. Clinical guidelines are recommendations on the appropriate treatment and care of people with specific diseases and conditions within the NHS in England and Wales. Clinical guidelines are based on the best available evidence (Source: guidance.nice.org.uk/CG).
The NASS request was made in May 2010 and NASS is still waiting to hear back from NICE.